3
项与 BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) 相关的临床试验A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
A Single-Arm, Single-Center Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma
This is a single arm, single center clinical study evaluating the safety and efficacy of CAR-T treatment for multiple myeloma.
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With R/R MM Who Received Three or More Lines of Therapy
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
100 项与 BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) 相关的临床结果
100 项与 BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) 相关的转化医学
100 项与 BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) 相关的专利(医药)
100 项与 BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) 相关的药物交易